Patents Assigned to Research Cancer Institute of America
  • Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
    Patent number: 11890292
    Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: February 6, 2024
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
    Patent number: 11890269
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: February 6, 2024
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
    Patent number: 11369585
    Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one of quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 28, 2022
    Assignee: RESEARCH CANCER INSTITUTE OF AMERICA
    Inventor: Mohammed Amin Nezami
  • Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
    Patent number: 10966957
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: April 6, 2021
    Assignee: RESEARCH CANCER INSTITUTE OF AMERICA
    Inventor: Mohammed Amin Nezami
  • Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
    Patent number: 10016392
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: July 10, 2018
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Compositions for treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
    Patent number: 9364500
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 14, 2016
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
    Patent number: 8933078
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: November 26, 2011
    Date of Patent: January 13, 2015
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami